Ichihara K, Kano S, Satoh K, Nakai T, Fukutomi T, Okazaki Y, Kohri H
Department of Pharmacology, Hokkaido College of Pharmacy, Otaru, Japan.
Nutrition. 1997 May;13(5):462-4. doi: 10.1016/s0899-9007(96)00377-2.
OG-VI is a solution composed of 30 mM inosine, 30 mM sodium 5'-guanylate, 30 mM cytidine, 22.5 mM uridine, and 7.5 mM thymidine, expecting to use for total parenteral nutrition. We examined the effect of OG-VI on myocardial contractile dysfunction during reperfusion after ischemia (myocardial stunning) in dogs. Pentobarbital-anesthetized dogs were subjected to 20-min left anterior descending coronary artery ligation followed by 30-min reperfusion. Saline, OG-VI or its constituents [inosine and sodium 5'-guanylate mixture (IG), and cytidine, uridine, and thymidine mixture (CUT)], or 5-amino-4-imidazole carboxamide riboside (AICAr) was infused at 0.1 mL.kg-1.min-1, starting 30 min before the ischemia. The contractile function was determined by ultrasonometry and assessed as % segment shortening (%SS). %SS was markedly decreased by ischemia, and returned toward pre-ischemic level after reperfusion, although the recovery was incomplete. The %SS was almost completely recovered by OG-VI and IG, and to a lesser extent by AICAr; CUT was ineffective. In the presence of 1 mg.kg-1 of 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, a selective adenosine A1 receptor antagonist), cardioprotective effect of OG-VI on stunned myocardium was still observed. In conclusion, infusion of OG-VI improved myocardial contractile dysfunction in stunned myocardium. This effect was more potent than its constituents and AICAr. Adenosine A1 receptors are not involved in the mechanism.
OG-VI是一种由30 mM肌苷、30 mM 5'-鸟苷酸钠、30 mM胞苷、22.5 mM尿苷和7.5 mM胸苷组成的溶液,预期用于全胃肠外营养。我们研究了OG-VI对犬缺血后再灌注期间心肌收缩功能障碍(心肌顿抑)的影响。戊巴比妥麻醉的犬接受20分钟左冠状动脉前降支结扎,随后进行30分钟再灌注。在缺血前30分钟开始以0.1 mL·kg-1·min-1的速度输注生理盐水、OG-VI或其成分[肌苷和5'-鸟苷酸钠混合物(IG)以及胞苷、尿苷和胸苷混合物(CUT)],或5-氨基-4-咪唑甲酰胺核苷(AICAr)。通过超声心动图测定收缩功能,并以节段缩短百分比(%SS)进行评估。%SS因缺血而显著降低,再灌注后虽恢复不完全,但恢复至缺血前水平。OG-VI和IG几乎完全恢复了%SS,AICAr恢复程度较小;CUT无效。在存在1 mg·kg-1的8-环戊基-1,3-二丙基黄嘌呤(DPCPX,一种选择性腺苷A1受体拮抗剂)的情况下,仍观察到OG-VI对顿抑心肌的心脏保护作用。总之,输注OG-VI可改善顿抑心肌的心肌收缩功能障碍。这种作用比其成分和AICAr更强。腺苷A1受体不参与该机制。